Australia Anti-Infective Agents Market Size & Outlook
- Pharmaceuticals
- Infectious Disease Treatment
- anti infective agents market
- Infectious Disease Treatment
Global Market
Related Markets
Ask a question about the anti infective agents market
Australia anti-infective agents market highlights
- The Australia anti-infective agents market generated a revenue of USD 1,757.2 million in 2025 and is expected to reach USD 2,055.7 million by 2033.
- The Australia market is expected to grow at a CAGR of 2.3% from 2026 to 2033.
- In terms of segment, antivirals was the largest revenue generating type in 2025.
- Antifungals is the most lucrative type segment registering the fastest growth during the forecast period.
Anti-infective agents market data book summary
| Market revenue in 2025 | USD 1,757.2 million |
| Market revenue in 2033 | USD 2,055.7 million |
| Growth rate | 2.3% (CAGR from 2026 to 2033) |
| Largest segment | Antivirals |
| Fastest growing segment | Antifungals |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibacterials, Antivirals, Antifungals |
| Key market players worldwide | Pfizer Inc, Abbott Laboratories, Gilead Sciences Inc, Bristol-Myers Squibb Co, Merck & Co Inc, Sandoz Group AG ADR, B. Braun, Novo Holdings, Mankind Pharma, Bayer AG, AstraZeneca PLC, Boehringer Ingelheim Pharma |
Other key industry trends
- In terms of revenue, Australia accounted for 1.3% of the global anti-infective agents market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China anti-infective agents market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 9,943.9 million by 2033.
The anti-infective agents market in Australia is experiencing notable growth, supported by active research and international collaboration. In September 2022, researchers from the University of Bern and the University of Queensland collaborated internationally to reveal that chemical compounds with specific metals can be highly effective against severe fungal infections.
Additionally, in October 2024, Shanghai MicuRx Pharmaceutical Co., Ltd. announced the successful completion of a Phase I clinical trial in Australia for MRX-5, an innovative oral antibacterial agent designed to treat nontuberculous mycobacterial (NTM) infections. These advancements highlight Australia's role in pioneering antiinfective research and clinical progress.
No credit card required*
Publish Date: Jun 25, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti Infective Agents Market
Anti Infective Agents Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| B. Braun | View profile | 10001+ | Chapeltown, Sheffield, United Kingdom, Europe | www.bbraun.co.uk |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| Mankind Pharma | View profile | 10001+ | New Delhi, Delhi, India, Asia | www.mankindpharma.com |
| Boehringer Ingelheim Pharma | View profile | 10001+ | Dortmund, Nordrhein-Westfalen, Germany, Europe | www.boehringer-ingelheim.de/unternehmensprofil/unser-unternehmen/standort-dortmund |
Australia anti infective agents market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Anti-infective Agents Market Outlook will help companies and investors design strategic landscapes.
Antivirals was the largest segment with a revenue share of 44.01% in 2025.
Horizon Databook has segmented the Australia anti-infective agents market based on antibacterials, antivirals, antifungals covering the revenue growth of each sub-segment from 2021 to 2033.
The anti-infective agents market in Australia is experiencing notable growth, supported by active research and international collaboration. In September 2022, researchers from the University of Bern and the University of Queensland collaborated internationally to reveal that chemical compounds with specific metals can be highly effective against severe fungal infections.
Additionally, in October 2024, Shanghai MicuRx Pharmaceutical Co., Ltd. announced the successful completion of a Phase I clinical trial in Australia for MRX-5, an innovative oral antibacterial agent designed to treat nontuberculous mycobacterial (NTM) infections. These advancements highlight Australia's role in pioneering antiinfective research and clinical progress.
- Australia Anti-Infective Agents Market Type Outlook (Revenue, USD Million , 2021-2033)
- Antibacterials
- Antivirals
- Antifungals
- Australia Anti-Infective Agents Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Parenteral
- Topical
- Others
- Australia Anti-Infective Agents Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Reasons to subscribe to anti infective agents market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of anti infective agents market databook
- Our clientele includes a mix of anti infective agents market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia anti infective agents market, including forecasts for subscribers. This country databook contains high-level insights into Australia anti infective agents market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Australia Anti-Infective Agents Market, 2021-2033 (US$M)
Australia Type - Anti-infective Agents Market Statistics, 2025 - 2033 (US$M)
